Profusa (PFSA) stock surged over 80% in pre-market trading after announcing a proposed $30 million acquisition of BioInsights PanOmics diagnostic platform. The equity deal grants Profusa exclusive rights to the technology and includes a 3% royalty for BioInsights. This strategic move allows Profusa to enter the molecular diagnostics space and enhance its monitoring technology.